Kornimate/medical-research-clean huggingface dataset:
hemospraytm for gastrointestinal bleeding from cancer

Conditions: Gastrointestinal Bleeding From Malignancy

Summary: title: the efficacy of hemostatic powder tc-325 versus standard endoscopic treatment for gastrointestinal bleeding from malignancy; a multi-center randomized trial background: gastrointestinal (gi) bleeding arising from malignant tumors is increasingly recognized as a result of oncological advances and improved detection methods. however, conventional endoscopic hemostatic methods are not reliable to control bleeding. it has a trend to be an effective hemostasis method for active gi bleeding from tumor, however, in view of the lack of rcts and large-scale studies, the efficacy of tc-325 is still inconclusive. objective: to evaluate the efficacy of tc325 in endoscopic hemostasis treatment for malignant gastrointestinal hemorrhage.the 24-hour, 72-hour, 30-day, 90-day and 180-day rebleeding rate were assessed as the outcomes of treatment as well as 6-month mortality. study design: single-blinded, multi-center, randomized-control trial study the intervention (experimental) arm: tc-325 alone (define failure if continued bleeding despite application of 1 syringes) the control arm: standard of (traditional) endoscopic treatments \*\* crossover is possible. inclusion criteria: patients with acute upper or lower gib from a lesion that is actively bleeding at index endoscopy (spurting or oozing) and is suspected to be malignant or diagnosed as malignancy from previous tissue diagnosis. exclusion criteria: patients less than 18 years old, previously included in the trial, ecog score 3 or 4, pregnancy/lactation, and/or bleeding from gi sources suspected of not being malignant. if an endoscopist is unsure of the malignant likelihood of the lesion, he/she will not be enrolled. sample size: 112 in total duration of participation for each volunteer: 180 days


Eligibility criteria:
inclusion criteria: * acute upper or lower gastrointestinal bleeding * endoscopy shows actively bleeding at index endoscopy (spurting or oozing) * bleeding from malignancy exclusion criteria: * less than 18 years old * previously included in the trial * eastern cooperative oncology group (ecog) score 3 or 4 * pregnancy/lactation * bleeding from gi sources suspected of not being malignant

Keywords: gi bleeding hemospray tc-325 malignancy tumor
cerebral perfusion in hypothermic circulatory arrest

Conditions: Cerebrovascular Circulation

Summary: selective antegrade cerebral perfusion (sacp) during aortic arch surgery in hypothermic circulatory arrest (hca) is an established method for intraoperative neuroprotection. although sacp is established as a beneficial method to reduce secondary neurological side effects due to brain-malperfusion, there are several parameters like sacp flow rate, perfusion pressure or temperature of the perfusate, where the optimal values remain unclear. the flow rate of the sacp-perfusate is increased according to center-specific standard-procedures. the optimal sacp flow rate, monitored by near infrared spectroscopy (nirs), is to be investigated in this single center clinical prospective observational study. 40 patients are enrolled over an estimated period of 14 months.


Eligibility criteria:
inclusion criteria: * age 18 years or older * elective cardiac surgery with cardiopulmonary bypass * hypothermic circulatory arrest * general informed consent signed exclusion criteria: - severe stenotis in cerebral arteries

Keywords: cardiopulmonary bypass hypothermic circulatory arrest aortic arch surgery
description of the cystatin c as an early nephrotoxic bio-marker in pediatric oncology

Conditions: Kidney Diseases

Summary: cisplatin and ifosfamide are commonly used drugs in chemotherapy. they are known to involve renal toxic threats in children given their immature kidney. this toxicity is increased especially after nephrectomy and/or concomitant radiotherapy. in pediatric oncology, the available evaluation methods of the renal function could be very restrictive to perform on children. in this study, the investigators intend to test the use of the cystatin c as an effective and reliable biological marker of renal toxicity in children treated with cisplatin and / or ifosfamide.

cisplatin and ifosfamide are commonly used drugs in chemotherapy. they are known to involve renal toxic threats in children given their immature kidney. this toxicity is increased especially after nephrectomy and/or concomitant radiotherapy. in pediatric oncology, the evaluation of the renal function is carried out according to the clinical trial protocols and to the center practices. to date, the standard methods (eg. creatinine clearance), as well as the available predictive formula (eg. schwartz formula) are not well adapted to monitor children renal function. indeed, the reliability of these methods depends on several parameters such as the diet and the muscle mass and could be very restrictive to perform on children. to circumvent these practical difficulties, the investigators intend to use the cystatin c as a biological marker of renal toxicity in children treated with cisplatin and / or ifosfamide. this cysteine protease has witnessed an upsurge of interest as an endogenous glomerular filtration rate marker and could be a good candidate to assess tubular toxicity when measured in urine. this study aims to describe the kinetic of the appearance of the urinary cystatin c and explore its proprieties as an early and cost-effective marker for glomerular and tubular renal toxicity in children. in addition, this method could allow enhancing the calculation models routinely used for glomerular filtration rate.

Eligibility criteria:
inclusion criteria: * children of 0 to18 years treated with cisplatin and / or ifosfamide in the hematology-oncology unit of toulouse university hospital of children regardless to the pathology they have been treated for * children with more than 4kg * written informed consent given by both parents or legal representative * patient covered by a social security agreement exclusion criteria: * impossibility to monitor and follow up the patient until the foreseeable end of the treatment (geographic reasons, etc.) * contraindication to edta clearance performing

Keywords: kidney toxicity
evaluating efficacy of a digital game therapeutic for children with autism

Conditions: Autism; Autism Spectrum Disorder

Summary: the following study aims to assess the efficacy of the game-based digital therapeutic, guesswhat, in improving adaptive socialization skills in children with autism spectrum disorder (asd). guesswhat is a mobile application (available for free for ios and android) which contains a suite of games: pro-social charades, emotion guessing, and quiz. participant families will use their personal smartphones to download the app and play it with their child according to a predetermined regimen.

the following study aims to understand the efficacy of the digital therapeutic, guesswhat, in improving socialization outcomes in children with autism spectrum disorder (asd) after regular use over 8 weeks. we will use a cross-over, waitlist control design to examine outcomes after 8 weeks. guesswhat is a mobile application (available for free for ios and android) which contains a suite of games: pro-social charades, emotion guessing, and quiz. participant families will use their personal smartphones to download the app and play it with their child according to a predetermined regimen. the study will enroll parents who are at least 18 years old and have a child between 3 and 12 years old with a formal asd diagnosis. parents will be asked to complete two clinical outcome measure questionnaires immediately prior to and up to 1 week after playing guesswhat with their child 3 times per week for 8 weeks.

Eligibility criteria:
inclusion criteria: 1. parent who is at least 18 years old of child with autism. 2. child with autism is between 3 and 12 years old at time of baseline data collection. 3. a professional diagnosis of autism that is able to be confirmed by negative score on a machine learning based algorithm using items from mobile autism risk assessment and video based classifier or by a copy of diagnostic report. exclusion criteria: 1. parent is unable to read the app in the offered languages (english, spanish, portuguese) 2. parent does not have an android or ios smartphone compatible with guesswhat app. 3. child has additional psychiatric or neurologic diagnoses including genetic syndromes or epilepsy in addition to autism.

Keywords: digital mobile health autism pediatrics
clomiphene citrate plus cabergoline in treatment of polycystic ovary syndrome

Conditions: Female Reproductive Problem

Summary: polycystic ovary syndrome (pcos) is the most common endocrine disorder of reproductive aged women and affects approximately 5-12 % of the female population. in 2003 in rotterdam , rotterdam diagnostic criteria were redefined pcos as affected individuals must have two out of the following three criteria: 1. oligo- and/or anovulation, (ovulation occurs less than once every 35 days). 2. hyperandrogenism, clinical signs include hirsutism, acne, alopecia, and frank virilization, while chemical indicators include raised concentrations of total testosterone and androstenedione , and elevated free androgen index. 3. polycystic ovaries on sonographic examination, presence of 12 or more follicles in either ovary measuring 2-9 mm in diameter, increased ovarian volume more than 10 cm3 and/or increase in stromal echogenicity. clearly, according to the rotterdam diagnostic criteria, the majority of women with pcos can be diagnosed without the need of laboratory examinations. clomiphene citrate (cc) is still the first-line medication for the induction of ovulation. it is an anti-estrogenic compound made up of two isomers, enclomiphene and zuclomiphene; the latter being the more potent of the two. it is a non-steroidal compound closely resembling estrogen. cc acts by blocking estrogen receptors, particularly in the hypothalamus, thereby signaling a lack of circulating estrogens and inducing a change in the pulsatile release of gonadotrophin-releasing hormone (gnrh). this induces release of follicle stimulating hormone from the anterior pituitary and is often enough to set the cycle of events leading to ovulation into motion. cabergoline, ergot-derived dopamine agonists with a very long half life, is an effective prolactin suppressor. cabergoline oral administration contains a weekly dose of 0.5 - 3 mg, which could be increased, if needed, to twice a week. this medicine has slight dopamine agonistic side effects, headache being the most common one. treatment in the very beginning should start with a partial dose (half a pill) at bedtime with a small amount of food. low incidence of side effects and its weekly dose has made cabergoline a choice drug for treatment of related diseases.


Eligibility criteria:
inclusion criteria: * 2 or more of pcos signs according to rotterdam diagnostic criteria (2003).- * primary or secondary infertility.- * absence of galactorrhoea * normal serum prolactin or slightly elevated (up to 50 ng/dl) * normal hysterosalpingography * normal spermogram exclusion criteria: * women on other line of treatment as aromatase inhibitors, gonadotrophins, or tamoxifen. * known hypersensitivity for clomiphene citrate or cabergoline. * other factors of infertility as tubal factor, uterine factor or male factor.
investigation of the femoral shortening osteotomy in the developmental dislocation of the hip (fsoddh)

Conditions: Hip Dislocation; Femur Head Necrosis

Summary: although older children and high dislocations may be more likely to require a femoral shortening osteotomy, the ultimate decision about whether or not to shorten a given femur should depend on the ease of femoral head reduction in that specific patient. adding a femoral shortening procedure increases operating time and blood loss, adds a second incision, and necessitates future hardware removal. in addition, an unnecessary femoral shortening osteotomy could overly decrease the soft tissue tension around the joint, putting the hip at risk for redislocation. this study was designed to explore an algorithm based on strict age and radiographic criteria that identify those without the need of femoral osteotomy.

developmental dislocation of the hip (ddh) is a common disease in children, and its incidence in china is about 9 ‰.there are many different methods in the treatment of ddh. although older children and high dislocations may be more likely to require a femoral shortening osteotomy, the ultimate decision about whether or not to shorten a given femur should depend on the ease of femoral head reduction in that specific patient. adding a femoral shortening procedure increases operating time and blood loss, adds a second incision, and necessitates future hardware removal. in addition, an unnecessary femoral shortening osteotomy could overly decrease the soft tissue tension around the joint, putting the hip at risk for redislocation. this study was designed to explore an algorithm based on strict age and radiographic criteria that identify those without the need of femoral osteotomy. from the investigators'clinical experiences and the published papers, younger patients (\<24 month of age) and low dislocations (tonnis level i or ii) were more likely to avoid a femoral shortening osteotomy.

Eligibility criteria:
inclusion criteria: 1. unilateral ddh,age 18-24month. 2. tonnis degree i or ii. 3. not receive any open treatment. exclusion criteria: 1. teratologic hip dislocations, 2. patients with mental, neurological disorders (such as hypoxic-ischemic encephalopathy, epilepsy and dementia) or significant barriers to growth, cerebral palsy, multiple joint contractures disease, dysfunction of liver and kidney , blood disorders, immune deficiency disease and ecg abnormalities. 3. any children with prior hip surgery were excluded from the series. 4. parents refused further treatment.

Keywords: hip dislocation congenital osteotomy femur head necrosis
effectiveness of the teacher module of the prevention program for externalizing problem behaviour in preschoolers

Conditions: Behavior Problem of Childhood and Adolescence

Summary: investigating effectiveness of the cognitive-behavioral based teacher training under routine care conditions by comparison of a baseline-interval with no special intervention to a following interval of pep for the kindergarten teachers only each focussing on one child (3-6 years old) that the teacher herself indicated as "needing special attention for externalising behaviour". effects on child symptoms and teachers behavior and burden within intervention-period are expected to be stronger than those during waiting-period.

findings of the pep-efficacy-study based on a randomised controlled sampling ((isrctn cct-napn-18918) using combined training-modules for parents and teachers showed positive effects on children's behaviour in the intervention-group. these effects in teacher's view were stronger than in the control-group but could not be proved to be statistically significant. moreover after this first step of evaluation there remain unanswered questions concerning the stability of effects after transferring the program in routine care. therefore the study is continued by an effectiveness-study.

Eligibility criteria:
inclusion criteria: * teacher's interest in participating in a specific further training * identification of a target child (externalizing problem behavior)by teacher * possibility of participation in at least 4 assessments (pre1, pre2, post,1stfu) exclusion criteria:

Keywords: externalizing problem behaviour in preschoolers
evaluating the effectiveness of mobile self-guided psychological interventions to reduce relapse in substance use disorder

Conditions: Substance Use Disorders; Addiction, Alcohol; Addiction, Substance

Summary: the aim of the study is to evaluate the effectiveness of mobile interventions in reducing craving and lapses in patients diagnosed with substance use disorder. in a two-armed, randomized controlled trial the efficacy of self-guided psychological intervention delivered via a mobile app (nałogometr 2.0) will be assessed. during the course of three months, participants will have access to intervention modules, based mainly on mindfulness and cognitive behavioral therapy (cbt). with the use of ecological momentary assessment (ema), longitudinal data on several variables related to craving and lapse risk will be collected. additionally, a questionnaire battery assessment - administered monthly - will measure severity of substance dependence, levels of anxiety, depression, and life satisfaction.

the aim of the study is to evaluate the effectiveness of mobile interventions in reducing craving and lapses in patients diagnosed with substance use disorder. participants will be recruited from clinical patients receiving either in-patient or out-patient treatments for substance use disorder (sud) and enrolled in one of three groups: 1) patients with alcohol addiction, 2) patients with cross-addiction (alcohol and stimulants), 3) patients with cannabis addiction. participants will be randomly assigned to either intervention or control condition. the mobile interventions will be delivered via a mobile app nałogometr 2.0, freely available. participants in the intervention condition will have free access to all of the app functionalities, while the control group won't gain access to the interventions until after study completion. interventions consist of audio-guided, short sessions on gratitude, thoughts management, motivation, relaxation, audio-guided mindfulness sessions concentrated on raising awareness of emotions and body signals or coping with stress, as well as cbt-based written sessions grounded in thought management and journaling techniques. with the use of ecological momentary assessment (ema), longitudinal data on several variables related to craving and lapse risk will be collected. additionally, a questionnaire battery assessment - administered at baseline, after one month, after two months, and after three months - will measure severity of substance dependence, levels of anxiety, depression, and life satisfaction.

Eligibility criteria:
inclusion criteria: * diagnosis of a substance use disorder (sud) * addiction to either alcohol, cannabis, or cross-addiction (alcohol + stimulants) * min. 18 years of age * fluent polish speakers * users of android or ios smartphones exclusion criteria: -

Keywords: mhealth substance use disorder alcohol cannabis stimulants
predictive biomarkers in patients with advanced hepatocellular carcinoma treated with systemic therapy

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is the third most common cause of cancer-related deaths worldwide, and hcc is more frequently observed in asia, including south korea. as hcc is often accompanied by chronic hepatitis b or c virus and liver cirrhosis, treatment of hcc consider not only the tumor but also various factors such as liver function and the patient's performance status. local treatment and surgery are possible in the early stages of hcc. however, it has a high recurrence rate even after curative surgeries due to underlying cirrhosis and the tumor microenvironment. although several studies have investigated gene mutations and differences in treatment response in advanced hcc through next-generation sequencing (ngs), studies on transcriptome analysis of advanced hcc through rna-sequencing are hard to find, with a need for future research into precise classification and clinical significance of hcc based on multi-omics data.

to establish multi-omics data and discover biomarkers highly associated with treatment response in hcc patients

Eligibility criteria:
inclusion criteria: * those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study. * patients who have been diagnosed with unresectable advanced hcc through imaging, histological, or cytological tests. * patients who underwent an ngs test with advanced hcc tissues * patients who are scheduled to receive systemic treatment * patients with measurable lesions based on recist v1.1 * ecog performance status 0 or 1 * patients with a life expectancy of at least three months exclusion criteria: * patients who have systemic conditions accompanied by instability of vital signs, such as infections or organ failure * those with mental/neurological conditions or dementia who have difficulties understanding and completing the consent form * those who are assessed as not suitable for this study, at the discretion of the researcher

Keywords: hepatocellular carcinoma
comparison of the sacroiliac manipulation and kinesiological tape in basketball players

Conditions: Sacroiliac Joint Dysfunction

Summary: in the usa, basketball is the most popular team sport for boys and girls enrolled in the 2003-2004 school year. many countries offer opportunities for young people to learn the game in a variety of settings, from physical education classes, school competitions, public and private sports organizations to community entertainment programmes. while the usa has long been seen as the dominant power in basketball, recent results in competitions such as the 1988 and 2004 men's olympic games and 2002 world championships show the rest of the world is closing the gap. basketball continues to spread around the world, thanks to ongoing development programs for children and youth .

one of the important parameters of postural control during landing after jump is stabilization time. there are several studies proving the curative effect of kinesio taping. however, studies investigating the effect of sacroiliac chiropractic manipulation are more limited than kinesio taping studies. there are fewer studies evaluating the performance of trait juvenile basketball players. although there is evidence showing the effect of manipulation on performance, botelho et al. state that scientific evidence in this area is lacking.

Eligibility criteria:
inclusion criteria * being a licensed basketball player in amateur leagues in istanbul * being between the ages of 18-25 * being a man * voluntarily participating in the study * not having a verbal communication barrier exclusion criteria * being under 18 years old or over 25 years old * spondylolysis or spondylolisthesis * neurological problems (acute myelopathy, spinal cord compression, cauda equina syndrome, radicular impingement) * hypermobile joints * acute fractures * intracanalicular hematomas * spinal cord hematomas in the spine * postoperative fixation prostheses * neoplastic diseases of muscle or other tissues * to have a surgical operation on the knee and waist region in the last year * osteoporosis with risk of fracture * vertebrobasilar insufficiency

Keywords: balance jump